Home
About
About Anagenics
Board of Directors
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2024
2023
2022
2021
2020
2019
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
The New Biotech Reports on Cellmid Limited
Home
The New Biotech Reports on Cellmid Limited
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
$26M Capped ASX Stock Generating Millions in Revenue
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
New ASX Listing: $15M Capped Stock with phase 2 Trialled Cancer Drug
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
US Sales unlocked for CDY: Pathway to $100M Revenue in Near Term
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
CDY Sales up to 72%: $100M Targets in Place
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
CDY Backs Hair research growth for 2017 as it capitalizes on US entry
